Ascletis' ASC30 obesity drug shows 75-day half-life in US Study
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
Brenntag will supply Food & Nutrition customers in the United States and Canada with Lallemand’s renowned Nutrilife baking enzyme range
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
CRISPR-based detection enables highly specific molecular recognition
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Subscribe To Our Newsletter & Stay Updated